BAOLAI INTERNATIONAL PHARMACEUTICAL INC – Trademark Portfolio

Entity Type: 03

BAOLAI INTERNATIONAL PHARMACEUTICAL INC holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 30 (Staple Foods) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include PONGDAY and STYIYEA. The owner is based in BOULDER, CO.

4084 GREENBRIAR BLVD,

BOULDER, CO 80305

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

STYIYEA
STYIYEA
Registered 2021
PONGDAY
PONGDAY
Registered 2021

Trademark Classifications

BAOLAI INTERNATIONAL PHARMACEUTICAL INC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

30
Staple Foods (2 filings)

Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations

Frequently Asked Questions

How many trademarks does BAOLAI INTERNATIONAL PHARMACEUTICAL INC have?

BAOLAI INTERNATIONAL PHARMACEUTICAL INC has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does BAOLAI INTERNATIONAL PHARMACEUTICAL INC file in?

BAOLAI INTERNATIONAL PHARMACEUTICAL INC files trademarks across 1 Nice Classification class. The most active classes are Class 30 (Staple Foods). Class 30 covers coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations.

What are BAOLAI INTERNATIONAL PHARMACEUTICAL INC's most well-known trademarks?

BAOLAI INTERNATIONAL PHARMACEUTICAL INC's registered trademark portfolio includes well-known marks such as PONGDAY and STYIYEA. These are among 2 currently registered trademarks in the portfolio.

What is BAOLAI INTERNATIONAL PHARMACEUTICAL INC's trademark registration success rate?

BAOLAI INTERNATIONAL PHARMACEUTICAL INC has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.